Corcept Therapeutics, Inc. (CORT)
72.77
+1.14
(+1.59%)
USD |
NASDAQ |
Nov 06, 16:00
72.76
-0.01
(-0.01%)
After-Hours: 20:00
Corcept Therapeutics Cash from Operations (Quarterly) : 142.89M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 142.89M |
| June 30, 2026 | 33.54M |
| March 31, 2026 | -16.77M |
| December 31, 2025 | 38.45M |
| September 30, 2025 | 54.48M |
| June 30, 2025 | 43.94M |
| March 31, 2025 | 4.77M |
| December 31, 2024 | 59.30M |
| September 30, 2024 | 73.83M |
| June 30, 2024 | 41.18M |
| March 31, 2024 | 23.76M |
| December 31, 2023 | 5.887M |
| September 30, 2023 | 52.91M |
| June 30, 2023 | 42.29M |
| March 31, 2023 | 25.96M |
| December 31, 2022 | 33.39M |
| September 30, 2022 | 33.65M |
| June 30, 2022 | 18.04M |
| March 31, 2022 | 35.25M |
| December 31, 2021 | 49.43M |
| September 30, 2021 | 48.70M |
| June 30, 2021 | 44.34M |
| March 31, 2021 | 25.42M |
| December 31, 2020 | 35.07M |
| September 30, 2020 | 30.44M |
| Date | Value |
|---|---|
| June 30, 2020 | 53.19M |
| March 31, 2020 | 33.27M |
| December 31, 2019 | 48.45M |
| September 30, 2019 | 38.43M |
| June 30, 2019 | 25.56M |
| March 31, 2019 | 23.68M |
| December 31, 2018 | 21.52M |
| September 30, 2018 | 44.50M |
| June 30, 2018 | 15.21M |
| March 31, 2018 | 34.43M |
| December 31, 2017 | 24.88M |
| September 30, 2017 | 10.92M |
| June 30, 2017 | 15.57M |
| March 31, 2017 | 9.561M |
| December 31, 2016 | 4.569M |
| September 30, 2016 | 8.935M |
| June 30, 2016 | 1.59M |
| March 31, 2016 | 3.297M |
| December 31, 2015 | 4.163M |
| September 30, 2015 | 0.883M |
| June 30, 2015 | -0.139M |
| March 31, 2015 | -1.777M |
| December 31, 2014 | -1.403M |
| September 30, 2014 | -5.929M |
| June 30, 2014 | -8.984M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Pfizer Inc. | 5.375B |
| Phibro Animal Health Corp. | -- |
| Illumina, Inc. | 419.00M |
| Eli Lilly & Co. | 11.40B |
| Merck & Co., Inc. | 6.558B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -131.99M |
| Cash from Financing (Quarterly) | -23.88M |
| Free Cash Flow | 194.62M |
| Free Cash Flow Per Share (Quarterly) | 1.154 |
| Free Cash Flow to Equity (Quarterly) | 142.61M |
| Free Cash Flow to Firm (Quarterly) | 142.18M |
| Free Cash Flow Yield | 2.30% |